Genmab A/S Sponsored ADR

GMAB Healthcare Biotechnology

Genmab A/S Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $3.7 billion, up 19.2% from fiscal 2024. In the quarter to June 2026, revenue grew 24.9%, EPS fell 9.26% and free cash flow fell 7.69%, each against the same quarter a year earlier. Revenue growth for three consecutive years, operating cash flow growth for three.

37.00 0.82 −2.17%
Market cap
$22.6B
P/E
29.1×
Fwd P/E
21.0×
Dividend yield
—
F-score
4/9
Altman Z
2.78
Beneish M
−3.00
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Piotroski F-Score
4 4 4 7

+8 more TTM periods

ROE
14.00% 14.96% 17.53% 28.38%
ROA
8.30% 8.66% 9.99% 23.07%
ROIC
6.99% 7.05% 7.08% 35.18%
Return on Tangible Assets
43.83% 53.38% 59.78% 38.30%
Average Days of Receivables
113.10 96.47 113.03 106.50
Free Cash Flow per Share
(10.35) (9.99) (9.79) 1.93
Free Cash Flow
(6,347.00) (6,306.00) (6,084.00) 1,188.89
Other line items

Show all line items

Columns are period end dates